Cytosorbents (NASDAQ: CTSO) and Harvard Bioscience (NASDAQ:HBIO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, dividends, risk and institutional ownership.
Valuation & Earnings
This table compares Cytosorbents and Harvard Bioscience’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cytosorbents||$15.15 million||15.76||-$8.46 million||($0.31)||-26.13|
|Harvard Bioscience||$101.88 million||1.63||-$870,000.00||($0.02)||-237.50|
This table compares Cytosorbents and Harvard Bioscience’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Cytosorbents has a beta of -0.17, meaning that its share price is 117% less volatile than the S&P 500. Comparatively, Harvard Bioscience has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500.
This is a summary of current ratings for Cytosorbents and Harvard Bioscience, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Cytosorbents presently has a consensus target price of $11.05, suggesting a potential upside of 36.42%. Harvard Bioscience has a consensus target price of $9.00, suggesting a potential upside of 89.47%. Given Harvard Bioscience’s higher probable upside, analysts clearly believe Harvard Bioscience is more favorable than Cytosorbents.
Insider and Institutional Ownership
11.1% of Cytosorbents shares are held by institutional investors. Comparatively, 63.5% of Harvard Bioscience shares are held by institutional investors. 5.6% of Cytosorbents shares are held by company insiders. Comparatively, 9.8% of Harvard Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Harvard Bioscience beats Cytosorbents on 10 of the 13 factors compared between the two stocks.
Cytosorbents Company Profile
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.
Harvard Bioscience Company Profile
Harvard Bioscience, Inc. is a developer, manufacturer and marketer of a range of scientific instruments, systems and lab consumables used for basic research, drug discovery, clinical and environmental testing. The Company’s products are sold to thousands of researchers in over 100 countries through its global sales organization, Websites, catalogs and through distributors. The Company’s product range is organized into three commercial product families: Cell and Animal Physiology (CAP), Lab Products and Services (LPS), and Molecular Separation and Analysis (MSA). The Company sells these products under brand names, including Harvard Apparatus, KD Scientific, Denville Scientific, AHN, Hoefer, Biochrom, BTX, Warner Instruments, MCS, HEKA, Hugo Sachs Elektronik, Panlab, Coulbourn Instruments, TBSI and CMA Microdialysis. The Company’s products consist of instruments, consumables and systems that are made up of various individual products.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.